Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Lone survivor
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
Comment by Inthepezon Sep 27, 2021 11:37am
84 Views
Post# 33923990

RE:RE:RE:Lone survivor

RE:RE:RE:Lone survivor Lmao yes !diot, ill keep reminding you. You’re synonymous with that. And I’ll keep reminding the forum in case and you one isn’t familiar with your stupidity.

please post more pics. I hope your gravestone has a pic of that with your handle rarbar99 etched on it. Because we all know you paid for it and not your daddy. 




quote=Rarbar99]

 

Inthepez wrote: Lmao at the narcissisim. You’re assuming no has sold. Your posts reflect what an idiot you are and the attachments issues you have. Seek therapy for your abandonment issues. 

Or keep posting pics of daddy’s car lmao 

 

 

My $250k car still has you in your feelings huh?

You're going to remember that photo until the day you die. It's going to be etched onto your brain for the rest of your life and when you die I'll buy you a custom gravestone that just shows the photo. 
 

[/quote]

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities